Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2013, 5(2), 676-713; doi:10.3390/cancers5020676
Article

Epigenetics and Colorectal Cancer Pathogenesis

 and *
Received: 21 March 2013; in revised form: 22 May 2013 / Accepted: 24 May 2013 / Published: 5 June 2013
(This article belongs to the Special Issue Cancer Epigenetics)
View Full-Text   |   Download PDF [603 KB, uploaded 5 June 2013]
Abstract: Colorectal cancer (CRC) develops through a multistage process that results from the progressive accumulation of genetic mutations, and frequently as a result of mutations in the Wnt signaling pathway. However, it has become evident over the past two decades that epigenetic alterations of the chromatin, particularly the chromatin components in the promoter regions of tumor suppressors and oncogenes, play key roles in CRC pathogenesis. Epigenetic regulation is organized at multiple levels, involving primarily DNA methylation and selective histone modifications in cancer cells. Assessment of the CRC epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has thousands of abnormally methylated genes. Although relatively less is known about the patterns of specific histone modifications in CRC, selective histone modifications and resultant chromatin conformation have been shown to act, in concert with DNA methylation, to regulate gene expression to mediate CRC pathogenesis. Moreover, it is now clear that not only DNA methylation but also histone modifications are reversible processes. The increased understanding of epigenetic regulation of gene expression in the context of CRC pathogenesis has led to development of epigenetic biomarkers for CRC diagnosis and epigenetic drugs for CRC therapy.
Keywords: colorectal cancer; DNMT; HDAC; HMTase; epigenetic therapy colorectal cancer; DNMT; HDAC; HMTase; epigenetic therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Bardhan, K.; Liu, K. Epigenetics and Colorectal Cancer Pathogenesis. Cancers 2013, 5, 676-713.

AMA Style

Bardhan K, Liu K. Epigenetics and Colorectal Cancer Pathogenesis. Cancers. 2013; 5(2):676-713.

Chicago/Turabian Style

Bardhan, Kankana; Liu, Kebin. 2013. "Epigenetics and Colorectal Cancer Pathogenesis." Cancers 5, no. 2: 676-713.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert